Surrogate Endpoint vs Outcome: Do Better Lab Numbers Mean Better Health?

A marker moving and a life improving are two different claims, and only one of them requires an outcome trial.

Better lab numbers are not the same thing as better health. Surrogate endpoint vs outcome is the difference between a marker a study measures because it is fast, like A1c or LDL, and the thing you actually care about, like a heart attack that never happens. Often the marker tracks the outcome. Sometimes it moves on its own, and only a long trial shows which.

A stand-in, and why studies use one

A surrogate is a substitute measurement. Researchers reach for one because waiting on real events takes years, thousands of people, and funding most studies never get. Blood pressure, A1c, LDL cholesterol, bone density, the number on a scale: each is standing in for something else.

The substitution rests on an assumption. Move the marker and the thing you care about moves with it.

Often that assumption holds up. It is still an assumption, and it is the part a headline rarely has room for.

What does an outcome trial actually count?

Events, in people. Deaths, heart attacks, strokes, admissions for heart failure, the start of dialysis, vision lost. Participants are randomized, followed for years, and then somebody counts what happened in each group.

Those events are uncommon, so the study has to be large and it has to run a long time. A trial can show an LDL change in twelve weeks. Showing that fewer people had strokes can take five years and tens of thousands of participants. Marker studies outnumber outcome trials by a wide margin for exactly that reason, so when a medication has a dedicated cardiovascular outcome trial behind it, somebody paid for a hard answer.

When a marker pointed the wrong way

The Cardiac Arrhythmia Suppression Trial is the example I keep coming back to. Two antiarrhythmic drugs, encainide and flecainide, did what they were meant to do to the marker: they suppressed the extra beats that follow a heart attack, beats that track with sudden death. Then the trial counted deaths, found more of them in the treated group, and stopped early. The results were published in the New England Journal of Medicine in 1991.

Cardiology ran that trial on itself and changed practice on the answer. It is a large part of why regulators now want counted events before accepting that a moving marker means a healthier patient. None of which is a reason to worry about a medication you take today. It is a reason to ask what was counted.

Where does body weight sit on that scale?

Weight is a surrogate. So is waist circumference, and so is the body composition readout from a scan. None of them is the health event you are hoping to avoid. Each is a measurement that tends to travel with those events across large populations.

Hold that in mind when you read the figures that get quoted most. In the STEP trials (NEJM 2021), brand semaglutide 2.4 mg as studied averaged 14.9 percent of body weight over 68 weeks alongside lifestyle changes, and about one in three participants reached 20 percent or more. In SURMOUNT-1 (NEJM 2022), brand tirzepatide at the highest studied dose averaged about 20.9 percent over 72 weeks. Both are trials of the FDA-approved brand products. Results vary by individual, and those are trial averages rather than anything a clinic can promise you.

They are also weight figures, not counts of heart attacks.

So does the weight loss matter or not?

It matters, and there is a specific trial to point to. SELECT (NEJM 2023) enrolled adults with established cardiovascular disease who had overweight or obesity but not diabetes, and reported fewer major adverse cardiovascular events on brand semaglutide 2.4 mg than on placebo. Counted events, in people, over years. It studied the FDA-approved brand product, at one dose, in one population. Results vary by individual.

Two things there are easy to overstate. A benefit found in people with established cardiovascular disease does not carry automatically to someone at low risk, or to a different dose, or to a different product. And we do not know how much of it follows from the weight lost rather than from other effects on blood vessels, inflammation, or blood pressure.

The outcome evidence for the brand product exists. Why it works is not settled.

What is the one question worth asking of any health claim?

Was a hard outcome measured, or was only a marker measured?

Ask it of anything I write here, this article included. Then ask it of a supplement ad, a study summary in your feed, a wellness product that promises to optimize your metabolism.

A few follow-ups:

• What exactly was counted? A number in blood, or something that happened to a person.
• Who was enrolled? A benefit found at high cardiovascular risk may not apply at low risk.
• Is the claim about the same product that was studied? This is the standard I hold our own pages to.
• If only a marker moved, is anyone running the outcome trial? Sometimes the answer is nobody, and that is worth knowing.

How this applies to compounded semaglutide and tirzepatide

Directly, and I would rather say it plainly. Compounded semaglutide and tirzepatide are not FDA-approved, are not identical to the brand versions, and results vary by individual. They have not been through outcome trials of their own. Describing them as though they carry the brand trial evidence would be the exact error this article is about.

Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. New Hope Weight Loss is not affiliated with or endorsed by these companies.

Compounded medications are dispensed by state-licensed compounding pharmacies operating under section 503A after patient-specific and location-specific verification, and only if a prescription is approved and the pharmacy can fulfill it for the patient location, with packaging and shipping confirmed before fulfillment.

What I do with lab numbers in clinic

I still order them. Markers are how I track safety and catch a problem early, and I would be a worse physician without them.

What changed over the years is how I talk about them. A falling A1c is a good sign. It is not a promise. When someone brings a printout with one value circled, I try to answer the question behind the circle: what is that number standing in for, and how tight is the link. Sometimes it is strong. Sometimes the honest answer is that it is looser than the circle suggests, and saying so is part of the job.

Our pricing, our compliance language, and how to reach us

New Hope Weight Loss and Wellness is a cash-pay telehealth practice, physically located in Costa Mesa, California, with Dr. Anjmun Sharma, MD as Medical Director. Telehealth, prescribing, and shipping depend on patient location and are confirmed before any treatment decision.

Pricing is published up front so there is no coverage guesswork. Initial physician review is $119 one-time, covering the doctor review and the prescription if approved; medication is billed separately. Compounded semaglutide is $499 per 90 days, or $166 per month, about $5.50 a day. Compounded tirzepatide starts at $699 per 90 days, or $233 per month, about $7.70 a day. These compounded medications are not FDA-approved, are not identical to the brand versions, and results vary by individual.

The one-month introduction, which we call the Skeptic's Trial, is $199, an introductory offer and not a clinical trial. It covers a physician evaluation plus, only if a prescription is approved and the dispensing pharmacy can fulfill it for the patient's location, one month of compounded semaglutide. If the review finds you are not a candidate, the medication portion is refunded and the evaluation fee covers the work performed. HSA and FSA are accepted, and financing is available through Cherry, Klarna, and Affirm, with terms set by the provider.

The 2-minute quiz on this site prepares you for a consultation. It does not determine eligibility and it does not guarantee a prescription. English (657) 837-3342, Spanish (213) 214-3325 by WhatsApp.

Frequently asked questions

This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.